Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial.

Date publication

mai 2017

Journal

Breast (Edinburgh, Scotland)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier

Tous les auteurs :
Gligorov J, Curigliano G, Müller V, Knoop A, Jenkins V, Verma S, Osborne S, Lauer S, Machackova Z, Fallowfield L, Pivot X

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28549309

Résumé

To assess the safety and tolerability of switching between subcutaneous (SC) and intravenous (IV) trastuzumab in the PrefHer study (NCT01401166).

Mots clés

Breast cancer, HER2/neu, Intravenous, Patient preference, Subcutaneous, Trastuzumab

Référence

Breast. 2017 May;34:89-95